Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Receptor Tyrosine Kinase And Downstream Signalling Analysis In Diffuse Malignant Peritoneal Mesothelioma.

F. Perrone, G. Jocollé, M. Pennati, M. Deraco, D. Baratti, S. Brich, M. Orsenigo, E. Tarantino, C. De Marco, C. Bertan, A. Cabras, R. Bertulli, M. Pierotti, N. Zaffaroni, S. Pilotti
Published 2010 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Our aim was to assess the activation profile of EGFR, PDGFRB and PDGFRA receptor tyrosine kinases (RTK) and their downstream effectors in a series of cryopreserved diffuse malignant peritoneal mesothelioma (DMPM) surgical specimens to discover the targets for drug inhibition. We also made a complementary analysis of the cytotoxic effects of some kinase inhibitors on the proliferation of the human peritoneal mesothelioma STO cell line. We found the expression/phosphorylation of EGFR and PDGFRB in most of the tumours, and PDGFRA activation in half. The expression of the cognate ligands TGF-α, PDGFB and PDGFA in the absence of RTK mutation and amplification suggested the presence of an autocrine/paracrine loop. There was also evidence of EGFR and PDGFRB co-activation. RTK downstream signalling analysis demonstrated the activation/expression of ERK1/2, AKT and mTOR, together with S6 and 4EBP1, in almost all the DMPMs. No KRAS/BRAF mutations, PI3KCA mutations/amplifications or PTEN inactivation were observed. Real-time polymerase chain reaction revealed the decreased expression of TSC1 c-DNA in half of the tumours. In vitro cytotoxicity studies showed the STO cell line to be resistant to gefitinib and sensitive to sequential treatment with RAD001 and sorafenib; these findings were consistent with the presence of the KRAS mutation G12D in these cells although it was not detectable in the original tumour. Our results highlight the ligand-dependent activation and co-activation of EGFR and PDGFRB, as well as a connection between these activated RTKs and the downstream mTOR pathway, thus supporting the role of combined treatment with RTK and mTOR inhibitors in DMPM.
This paper references
10.1136/thx.2007.085241
EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors
H. Kothmaier (2007)
10.1016/J.LUNGCAN.2005.04.010
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
10.1097/CAD.0b013e32831fb500
Sorafenib tosylate in advanced kidney cancer: past, present and future
C. Porta (2009)
10.1215/15228517-2009-003
PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.
F. Perrone (2009)
10.1043/1543-2165(2004)128<538:TSOKCI>2.0.CO;2
The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature.
K. Butnor (2004)
10.1101/GAD.1314605
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2.
B. Manning (2005)
10.1002/path.1945
PDGFRα, PDGFRβ and KIT expression/activation in conventional chondrosarcoma
M. S. Lagonigro (2006)
10.1093/JNCI/82.13.1107
New colorimetric cytotoxicity assay for anticancer-drug screening.
Philip Skehan (1990)
10.1016/j.lungcan.2008.08.013
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
G. Cartenì (2009)
10.1158/1078-0432.CCR-08-2050
Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma
S. Stacchiotti (2009)
10.1158/1078-0432.CCR-06-1584
Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas
E. Tamborini (2006)
10.1245/ASO.2006.03.045
Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion
M. Deraco (2006)
10.1158/1078-0432.CCR-08-0099
Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma
R. Villa (2008)
10.1158/1078-0432.CCR-04-1884
P16 Loss and Mitotic Activity Predict Poor Survival in Patients with Peritoneal Malignant Mesothelioma
A. Borczuk (2005)
10.1002/jso.21055
Consensus statement on peritoneal mesothelioma
M. Deraco (2008)
10.1245/s10434-008-0206-6
Novel and Existing Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor are Predictors of Optimal Resectability in Malignant Peritoneal Mesothelioma
J. Foster (2008)
10.1172/JCI34739
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.
A. Carracedo (2008)
10.1200/JCO.2009.23.9640
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
T. Yan (2009)
And Ladanyi M Homozygous deletion of CDKN 2 A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas
PB Illei (2003)
10.1158/1078-0432.CCR-06-1759
Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma
F. Perrone (2006)
10.1245/s10434-008-0219-1
Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
D. Baratti (2008)
10.1200/JCO.2008.21.1862
Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer.
G. Giaccone (2009)
Et al.Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo
AW Langerak (1996)
10.1016/j.molonc.2009.10.003
Targeted Therapies: The Rare Cancer Paradigm
M. Pierotti (2010)
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
P. Illei (2003)
10.1002/cncr.21239
Diffuse malignant mesothelioma of the peritoneum
D. Nonaka (2005)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma.
M. Lagonigro (2006)
10.1093/annonc/mdn541
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.
F. Perrone (2009)
10.1038/modpathol.2008.45
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
S. Chiosea (2008)
10.1038/sj.onc.1209809
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin–proteasome pathway as a therapeutic target in poor prognosis tumors
A. Borczuk (2007)
10.1155/2007/456839
Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma
N. Zaffaroni (2007)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1309/XL6K-8E62-9FLD-V8Q8
Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
F. Roberts (2001)
10.1093/carcin/bgp097
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
K. Kawaguchi (2009)
Malignant peritoneal mesothelioma – results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 2009;64:211–8
G Carteni (2009)
10.1038/modpathol.3800067
Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers
J. Trupiano (2004)
10.1002/path.2177
Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas
E. Tamborini (2007)
10.1007/s00280-006-0243-4
Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma
C. Porta (2006)
10.1158/1078-0432.CCR-03-0059
Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor β Tyrosine Kinase Receptors in Synovial Sarcoma
E. Tamborini (2004)
10.1002/(SICI)1096-9896(199602)178:2<151::AID-PATH425>3.0.CO;2-E
EXPRESSION OF PLATELET‐DERIVED GROWTH FACTOR (PDGF) AND PDGF RECEPTORS IN HUMAN MALIGNANT MESOTHELIOMA IN VITRO AND IN VIVO
A. Langerak (1996)
10.1016/0065-2571(84)90007-4
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.
T. Chou (1984)



This paper is referenced by
10.1002/jcp.26830
Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas
E. Sementino (2018)
10.1002/jso.21787
Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research
D. Baratti (2011)
10.3390/cells8101274
The Oncogenic Signaling Pathways in BRAF-Mutant Melanoma Cells Are Modulated by Naphthalene Diimide-Like G-Quadruplex Ligands
Marta Recagni (2019)
10.1097/JTO.0b013e318215a07d
Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy
M. Brevet (2011)
10.1016/j.mrgentox.2011.04.008
Crocidolite asbestos-induced signal pathway dysregulation in mesothelial cells.
H. Wang (2011)
Novel approaches to understanding Hent2 and hENT2-related proteins: From novelnuclear variants to global networks / Nuevos enfoques sobre el estudio de hENT2 y proteínas relacionadas: desde nuevas variantes nucleares a redes globales
Natàlia Grañé Boladeras (2012)
10.1111/j.1476-5381.2012.01873.x
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma
R. Favoni (2012)
10.1016/j.ejca.2013.05.027
Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
D. Baratti (2013)
10.1245/s10434-012-2845-x
The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
M. Deraco (2012)
10.1016/j.semcancer.2019.09.014
Translating Mesothelioma Molecular Genomics and Dependencies into Precision Oncology-Based Therapies.
T. K. Hinz (2019)
Oncogenes and Tumor Suppressors Nonampli fi ed FGFR 1 Is a Growth Driver in Malignant Pleural Mesothelioma
L. Marek (2014)
10.3389/fonc.2020.00101
Preclinical Models of Malignant Mesothelioma
J. Testa (2020)
10.1016/j.anndiagpath.2014.02.005
Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.
A. Tsao (2014)
10.1038/onc.2015.515
Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis
J. Musa (2016)
10.1016/j.phrs.2016.09.007
Pharmacogenomic analyzis of the responsiveness of gastrointestinal tumor cell lines to drug therapy: A transportome approach.
N. Grañé-Boladeras (2016)
10.3892/or.2012.1725
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Neetu Kalra (2012)
10.3390/ijms20225817
Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma
A. Belfiore (2019)
10.1007/978-3-030-16884-1_21
Peritoneal Mesothelioma: Diagnosis and Management
M. Deraco (2019)
10.1007/978-981-15-3773-8
Pathology of Peritoneal Metastases: The Unchartered Fields
Olivier Gléhen (2020)
10.1186/s13045-016-0387-6
Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism
Rihan El Bezawy (2017)
10.1371/journal.pone.0021370
Cambogin Is Preferentially Cytotoxic to Cells Expressing PDGFR
Z. Tian (2011)
10.1158/1541-7786.MCR-14-0038
Nonamplified FGFR1 Is a Growth Driver in Malignant Pleural Mesothelioma
L. Marek (2014)
10.23736/S0026-4806.19.06153-6
MiR-34a improve spatial cognitive ability of depression rats through ERK signaling pathway.
Yanglin Jiang (2019)
10.1038/bjc.2014.220
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
S. Zhou (2014)
10.1007/978-3-642-02322-4_43
Tumoren und tumorartige Läsionen des Peritoneums
F. Offner (2013)
Targeting mTOR as novel therapy for Human Malignant Mesothelioma
A. Mohamed (2011)
Semantic Scholar Logo Some data provided by SemanticScholar